Sanofi-Aventis

SNY-N

NYSE:SNY

52.30
0.32 (0.61%)
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.
More at Wikipedia

Analysis and Opinions about SNY-N

Signal
Opinion
Expert
Chart
DON'T BUY
DON'T BUY
June 10, 2021
Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.
Show full opinionHide full opinion
Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.
DON'T BUY
DON'T BUY
June 7, 2021
They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.
Show full opinionHide full opinion
They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.
David Driscoll
Price
$0.000
Owned
Unknown
BUY
BUY
May 17, 2021
A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.
Show full opinionHide full opinion
A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.
Jim Cramer - Mad Money
Price
$53.380
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 7, 2021

(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.

Show full opinionHide full opinion

(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.

Norman Levine
Price
$51.780
Owned
Yes
COMMENT
COMMENT
February 5, 2021
In late-2019, a new CEO arrive to turn things around by spinning off the so-so consumer business and making small acquisitions. However, Covid hit them hard, and their vaccine development has disappointed. Reported a solid quarter this morning with a slight revenue miss, but strong earnings beat and bullish guidance for 2021. The stock rose 2%. Will it get its groove back?
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
February 5, 2021
In late-2019, a new CEO arrive to turn things around by spinning off the so-so consumer business and making small acquisitions. However, Covid hit them hard, and their vaccine development has disappointed. Reported a solid quarter this morning with a slight revenue miss, but strong earnings beat and bullish guidance for 2021. The stock rose 2%. Will it get its groove back?
Jim Cramer - Mad Money
Price
$48.210
Owned
Unknown
BUY
BUY
December 22, 2020
A French pharma. He bought this not for its vaccine, but because it's a well-run pharma, not facing patent expirations, and has good growth and returns in the future. He doesn't know where their vaccine stands now, but if it works, it will certainly boost the stock. Has strong dividend and earnings growth.
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 22, 2020
A French pharma. He bought this not for its vaccine, but because it's a well-run pharma, not facing patent expirations, and has good growth and returns in the future. He doesn't know where their vaccine stands now, but if it works, it will certainly boost the stock. Has strong dividend and earnings growth.
Lorne Steinberg
Price
$47.830
Owned
Yes
TOP PICK
TOP PICK
December 3, 2020
Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription. It produces a drug for children aged 6-11 years with atopic dermatitis. Sales of the drug jumped almost 70% last year and it is on pace to earn the company $12 billion in revenues in the near future. The company is also vying to be another COVID-19 vaccine producer as it plans to introduce Phase 3 trials on a prospective candidate this month. It pays an excellent dividend, backed by a 38% payout ratio. We would buy SNY with a stop-loss at $45, looking towards an initial target of $61 -- 20% upside. Yield 3.36% (Analysts’ price target is $61.38)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 3, 2020
Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription. It produces a drug for children aged 6-11 years with atopic dermatitis. Sales of the drug jumped almost 70% last year and it is on pace to earn the company $12 billion in revenues in the near future. The company is also vying to be another COVID-19 vaccine producer as it plans to introduce Phase 3 trials on a prospective candidate this month. It pays an excellent dividend, backed by a 38% payout ratio. We would buy SNY with a stop-loss at $45, looking towards an initial target of $61 -- 20% upside. Yield 3.36% (Analysts’ price target is $61.38)
TOP PICK
TOP PICK
March 12, 2020
It is not economically sensitive even though the stock is getting hit. It is one of the biggest vaccine manufacturers in the world. They are working on a CoVid19 vaccine and they own an arthritis drug that could be a possible drug for treatment of CoVid19. (Analysts’ price target is $56.93)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
March 12, 2020
It is not economically sensitive even though the stock is getting hit. It is one of the biggest vaccine manufacturers in the world. They are working on a CoVid19 vaccine and they own an arthritis drug that could be a possible drug for treatment of CoVid19. (Analysts’ price target is $56.93)
Norman Levine
Price
$41.360
Owned
Yes
TOP PICK
TOP PICK
December 18, 2019
A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 18, 2019
A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)
Norman Levine
Price
$50.300
Owned
Yes
TOP PICK
TOP PICK
October 17, 2019
A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
October 17, 2019
A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)
Lorne Steinberg
Price
$46.590
Owned
Yes
PAST TOP PICK
PAST TOP PICK
August 14, 2019
(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
August 14, 2019
(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.
Norman Levine
Price
$41.750
Owned
Yes
WEAK BUY
WEAK BUY
July 17, 2019
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
Show full opinionHide full opinion
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
Paul MacDonald
Price
$41.570
Owned
Yes
PAST TOP PICK
PAST TOP PICK
July 3, 2019
(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.
Show full opinionHide full opinion
(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.
Norman Levine
Price
$44.000
Owned
Unknown
HOLD
HOLD
May 22, 2019
A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.
Show full opinionHide full opinion
A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.
Norman Levine
Price
$42.090
Owned
Yes
HOLD
HOLD
May 3, 2019
Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.
Show full opinionHide full opinion
Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.
Paul MacDonald
Price
$43.680
Owned
Unknown
Showing 1 to 15 of 33 entries

Sanofi-Aventis(SNY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 5

Stockchase rating for Sanofi-Aventis is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N

Is Sanofi-Aventis a buy or a sell?

In the last year, 5 stock analysts published opinions about SNY-N. 3 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Sanofi-Aventis.

Is Sanofi-Aventis a good investment or a top pick?

Sanofi-Aventis was recommended as a Top Pick by John O'Connell, CFA on 2021-06-10. Read the latest stock experts ratings for Sanofi-Aventis.

Why is Sanofi-Aventis stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Sanofi-Aventis worth watching?

5 stock analysts on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.

What is Sanofi-Aventis stock price?

On 2021-06-22, Sanofi-Aventis (SNY-N) stock closed at a price of $52.3.